Get the Stockscreener App
151.11
0.29%
0.43
After Hours:
150.00
-1.11
-0.73%
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $151.11, with a volume of 1.93M.
It is up +0.29% in the last 24 hours and up +21.04% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$150.68
Open:
$150.7
24h Volume:
1.93M
Relative Volume:
1.12
Market Cap:
$16.86B
Revenue:
$2.90B
Net Income/Loss:
$239.11M
P/E Ratio:
71.63
EPS:
2.1097
Net Cash Flow:
$492.62M
1W Performance:
+5.34%
1M Performance:
+21.04%
6M Performance:
+72.03%
1Y Performance:
+81.97%
1-Day Range:
$147.03
$151.99
1-Week Range:
$140.08
$152.26
52-Week Range:
$81.22
$152.26
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
151.11 | 16.86B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
675.00 | 249.58B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
224.49 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
412.56 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.79 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.37 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Form 144 REVVITY For: 27 September By Investing.com - Investing.com UK
Revvity declares $0.07 quarterly dividend for shareholders - scanx.trade
PKI4882935 Bond Profile: Coupon and Redemption - TradingView
Revvity options flow shows 156:1 call-to-put ratio ahead of Nov. 2026 expiry - Investing.com
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance Singapore
Revvity, Inc. (RVTY) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection - Yahoo Finance Singapore
New Products: Qiagen, Helix, Countable Labs, AtlasBio, Revvity, Agilent - GenomeWeb
Revvity Q2FY26 Results: Organic growth hits 3%, adjusted EPS $1.41 - scanx.trade
Full Transcript: Revvity Q2 2026 Earnings Call - Benzinga
Revvity (RVTY) Short Interest & Short Float | Updated Sep 2026 $RVTY - MarketBeat
Revvity stock gains 5.2 percent ahead of the open - AD HOC NEWS
Revvity Inc (RVTY) Shares Surge 6.0% -- What GF Score of 78 Tells Investors - gurufocus.com
Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years - Benzinga
Revvity shares rise as analyst target hike adds to momentum from deal and guidance - Quiver Quantitative
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo! Finance Canada
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Inc stock hits 52-week high at 149.72 USD By Investing.com - Investing.com India
Revvity Inc stock hits 52-week high at 149.72 USD - Investing.com
Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test - Yahoo Finance
Revvity, Inc. Launches GSP® T1D 3plex Kit For Early Detection Of Type 1 Diabetes - marketscreener.com
Revvity Shares Rise on Launch of Child Type 1 Diabetes Screening Test - marketscreener.com
RVTY Looks 20.9% Overvalued on GF Value™ as Insider Selling Pers - gurufocus.com
Revvity launches type 1 diabetes screening kit in Europe - Investing.com
Revvity launches type 1 diabetes screening kit in Europe By Investing.com - Investing.com Canada
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes - Business Wire
Leerink Partners Adjusts Revvity Price Target to $160 From $145, Maintains Outperform Rating - marketscreener.com
Insider Maxwell Krakowiak Sells 1,631 Shares of Revvity Inc (RVT - gurufocus.com
Is Revvity Stock Outperforming the Dow? - webull.com
Revvity CFO Maxwell Krakowiak sells $235,728 in RVTY stock - Investing.com India
Revvity CFO Maxwell Krakowiak sells $235,728 in RVTY stock By Investing.com - Investing.com Australia
Form 4 Revvity Inc For: 23 September - Investing.com India
After selling 1,631 shares, Revvity (RVTY) CFO holds 14,781 shares - Stock Titan
Understanding Momentum Shifts in (RVTY) - news.stocktradersdaily.com
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Revvity (RVTY) Is Getting Attention Today - Yahoo Finance
Revvity stock holds near USD 143 after target hike - AD HOC NEWS
Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Revvity stock heads into the open after a Goldman target hike - AD HOC NEWS
Revvity Inc. stock gains on Goldman Sachs price target hike - AD HOC NEWS
Revvity (NYSE: RVTY) shareholder may sell stock under Rule 144 - Stock Titan
Goldman Sachs Adjusts Price Target on Revvity to $140 From $100, Keeps Neutral Rating - Yahoo Finance
Revvity, Inc. (RVTY) Stock Analysis: A Healthcare Diagnostics Giant with a Cautious Analyst Outlook - DirectorsTalk Interviews
Revvity Inc. stock gains on Human Cell Design deal and recent rally - AD HOC NEWS
Senior Vice President of Global Operations Tajinder Vohra Sold A Bunch Of Shares In Revvity - simplywall.st
Revvity Inc. stock slips after CFRA downgrade but stays near 52-week high - AD HOC NEWS
ETFs Investing in Revvity, Inc. Stocks - TradingView
Revvity SVP Tajinder Vohra Sells 7,330 Shares Under 10b5-1 Trading Plan - kalkinemedia.com
Insider Tajinder Vohra Sells 7,330 Shares of Revvity Inc (RVTY) - GuruFocus
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Insider at Revvity (RVTY) sells stock under preset plan - Stock Titan
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):